AVAC: Global Advocacy for HIV Prevention
AVAC: Global Advocacy for HIV Prevention was founded in December 1995 to advocate for the development of a safe, effective, and accessible HIV vaccine. It seeks to promote increased funding and investment in HIV vaccine research by government agencies, private industry and non-governmental organizations; to identify barriers to the development of a vaccine; and to increase public awareness about the need for a well funded, coordinated HIV vaccine research program. It seeks to promote increased HIV vaccine advocacy efforts by community-based organizations and increased awareness about HIV vaccine development among AIDS-affected communities. It is committed to the principle that funds for HIV vaccine research are not to be taken from basic HIV research, drug development or prevention efforts.
Latest by AVAC: Global Advocacy for HIV Prevention
"Every member of the AVAC team in Madrid was moved and motivated by the Madrid conference," AVAC writes. "We know the work is not easy, nor is the world."
Real Women Don't Look Like Models: What the Latest Paper on Hormonal Contraception and HIV Risk Leaves Out
While there are modeling studies that look at lives saved versus lost because of these contraception methods, advocates are calling far and wide for better choices.
What is medical male circumcision and why is it a key part of combination HIV prevention? This fact sheet answers these questions and more.
What are microbicides, why do we need them, and what is the status of current microbicide research? This fact sheet answers those questions and more.
Carl Dieffenbach, Ph.D., director of NIH's Division of AIDS, recently met with advocates to provide them with his "rather intentionally provocative ideas, which will for sure get varying degrees of attention, praise and criticism."
Europe is the birthplace of the smallpox vaccine and the Renaissance, among other treasures. So why can't this continent that has brought forth such cornerstones of public health and flourishing civilization deliver oral PrEP?
You're invited to join a webinar with the World Health Organization on the newly released guidance on hormonal contraceptive eligibility for women at high risk of HIV.
Protection from pre-exposure prophylaxis doesn't happen overnight. How many doses does it take? Join AVAC for a webinar on the data behind "time to protection for PrEP."
"President Clinton should lay the foundation for ending the HIV/AIDS crisis by 2030," says Jeffrey Sachs, expert on global economic development and provocateur. "Tell her to knock down drug prices in the U.S. ... raise a miniscule US$10 billion a yea...
"When scientists work with (or as) advocates, or when politicians serve as (or team up with) activists, great things can happen," AVAC writes from the HIV Research for Prevention conference in Chicago.